Companion diagnostics developer Foundation Medicine has entered a strategic collaboration with multinational pharmaceutical company Merck KGaA, Germany, to develop companion diagnostics using FoundationOne CDx and FoundationOne Liquid CDx for selected cancer treatments in the US market. This is an extension of their previous partnership focused on data solutions, which was established in 2020.
The partnership aims to leverage Foundation Medicine's comprehensive genomic profiling tests to identify patients with genomic alterations that may benefit from specific targeted therapies. The collaboration will support the development of personalized treatment options for cancer patients by using molecular profiling to guide treatment decisions and optimize therapy development. This will enable oncologists to use FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to identify eligible patients for targeted therapies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.